Clinical Trial: Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS

U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472179) titled 'Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS' on Feb. 19.

Brief Summary: Women with PCOS with HOMA-IR >2 fulfilling inclusion and exclusion criteria are randomly allocated into two groups: group A: pioglitazone 30 mg once daily and group B: Metformin 500 thrice daily for 3 months.Each group contains 30 participants. Outcome variables are measured after 3 months.

Study Start Date: Aug. 12, 2024

Study Type: INTERVENTIONAL

Condition: PCOS(Insulin Resistant)

Intervention: DRUG: Pioglitazone 30 Mg Oral Tablet

pioglitazone 30 mg once daily for 3 months

DRUG: metfor...